ASM case reports · 2026
Chlamydia psittaci pneumonia in a patient using ustekinumab therapy for Crohn's disease.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dirks J A M C, Mulder L, Burgers K, Damoiseaux J G M C, Heddema E R
Аннотация
BACKGROUND: Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin-12 and interleukin-23, is widely used for immune-mediated diseases such as Crohn's disease. By modulating Th1 and Th17 pathways, ustekinumab may increase susceptibility to intracellular pathogens. We report the first case of Chlamydia psittaci pneumonia in a patient treated with ustekinumab.
CASE SUMMARY: A 27-year-old woman with Crohn's disease presented with severe community-acquired pneumonia, progressive hypoxemia, and pulmonary embolism 3 weeks after initiating ustekinumab therapy. Despite broad-spectrum antibiotics, clinical improvement was limited. Her exposure history revealed contact with multiple pet birds, several of which died recently. Polymerase chain reaction testing confirmed C. psittaci genotype A infection. Targeted treatment with doxycycline led to clinical recovery. Ustekinumab therapy was temporarily postponed.
CONCLUSION: This case highlights a potential association between ustekinumab and susceptibility to C. psittaci, a zoonotic intracellular pathogen. It underscores the importance of exposure history and considering atypical pathogens in immunocompromised patients. Clinicians should maintain vigilance for opportunistic infections in individuals receiving targeted biologic therapies.
CASE SUMMARY: A 27-year-old woman with Crohn's disease presented with severe community-acquired pneumonia, progressive hypoxemia, and pulmonary embolism 3 weeks after initiating ustekinumab therapy. Despite broad-spectrum antibiotics, clinical improvement was limited. Her exposure history revealed contact with multiple pet birds, several of which died recently. Polymerase chain reaction testing confirmed C. psittaci genotype A infection. Targeted treatment with doxycycline led to clinical recovery. Ustekinumab therapy was temporarily postponed.
CONCLUSION: This case highlights a potential association between ustekinumab and susceptibility to C. psittaci, a zoonotic intracellular pathogen. It underscores the importance of exposure history and considering atypical pathogens in immunocompromised patients. Clinicians should maintain vigilance for opportunistic infections in individuals receiving targeted biologic therapies.